Two Sigma Advisers LP Has $1.39 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX)

Two Sigma Advisers LP grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 164.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 180,000 shares of the biotechnology company's stock after buying an additional 112,000 shares during the quarter. Two Sigma Advisers LP owned about 0.36% of REGENXBIO worth $1,391,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Two Sigma Investments LP raised its holdings in REGENXBIO by 209.2% during the fourth quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company's stock worth $3,010,000 after purchasing an additional 263,495 shares in the last quarter. Rafferty Asset Management LLC increased its position in shares of REGENXBIO by 22.4% during the 4th quarter. Rafferty Asset Management LLC now owns 93,821 shares of the biotechnology company's stock valued at $725,000 after purchasing an additional 17,180 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of REGENXBIO in the 4th quarter worth $447,000. ProShare Advisors LLC lifted its holdings in shares of REGENXBIO by 22.4% in the fourth quarter. ProShare Advisors LLC now owns 15,314 shares of the biotechnology company's stock valued at $118,000 after buying an additional 2,800 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock valued at $10,222,000 after buying an additional 1,061,187 shares during the period. 88.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RGNX has been the topic of a number of research analyst reports. Wall Street Zen raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. The Goldman Sachs Group reduced their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, REGENXBIO has an average rating of "Moderate Buy" and an average price target of $31.63.

Insiders Place Their Bets

In other news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the transaction, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.79% of the company's stock.

REGENXBIO Trading Down 0.5%

RGNX stock traded down $0.05 during mid-day trading on Wednesday, reaching $10.08. 690,256 shares of the stock traded hands, compared to its average volume of 904,943. REGENXBIO Inc. has a 52-week low of $5.04 and a 52-week high of $15.36. The stock's fifty day moving average is $8.01 and its 200-day moving average is $7.95. The company has a market cap of $505.61 million, a P/E ratio of -2.00 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $89.01 million for the quarter, compared to analysts' expectations of $105.35 million. Equities research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.